Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 18,244 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Controlled Group Clear all

Conditions: Schizophrenia
Interventions: Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 29 more

Conditions: Autism Spectrum Disorders
Interventions: emotion regulation training; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Suicide, Aggression
Interventions: A-CWS, Standard Care Control; Behavioral
Lead sponsor: DePaul University; Other
Eligibility: 12 Years and older
Enrollment: 939 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epilepsy, Tonic-Clonic
Interventions: lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 80
States / cities: Alabaster, Alabama • Mobile, Alabama • Northport, Alabama + 71 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more

Conditions: Inflammatory Bowel Diseases, Colo-rectal Cancer
Interventions: no intervention will be given to patients.; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Patient Satisfaction
Interventions: Music; Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Premature Ventricular Contraction, Ventricular Tachycardia
Interventions: VIVO; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Obsessive-Compulsive Disorder
Interventions: Topiramate; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Occlusive Stroke
Interventions: Asahi Chikai Black 18 neurovascular guidewire; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Physical Activity, Social Responsibility
Interventions: DAID, Dog walking; Behavioral
Lead sponsor: Oregon State University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more

Conditions: Substance Abuse, Intimate Partner Violence (IPV), HIV Infections, Depression, Anxiety
Interventions: SER Familia; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Urinary Bladder, Overactive, Urinary Incontinence
Interventions: onabotulinumtoxinA, Placebo (saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 31
States / cities: Laguna Hills, California • Los Angeles, California • Orange, California + 27 more

Conditions: Overactive Bladder
Interventions: Omega 3 Fatty Acid, Placebo; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Systemic Lupus Erythematosus
Interventions: Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Torrance, California • Brandon, Florida • Miami, Florida + 10 more

Conditions: Patient Satisfaction
Interventions: Access to routine information, Access to website; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Drug Safety
Interventions: Placebo, VIA-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Obstructed Defecation Syndrome (ODS)
Interventions: Botulinum Toxin-A, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eosinophilic Esophagitis
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Constipation, Post-Op Complication
Interventions: Polyethylene Glycol Powder; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bay Shore, New York

Conditions: Crohn's Disease
Interventions: Epanova™ (Omega-3 Free Fatty Acids); Drug
Lead sponsor: Tillotts Pharma AG; Industry
Eligibility: 16 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 10
States / cities: Atlanta, Georgia • Chicago, Illinois • Urbana, Illinois + 6 more

Conditions: Major Depressive Disorder (MDD)
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 51
States / cities: Mesa, Arizona • Los Angeles, California • Oceanside, California + 42 more

Conditions: ACUTE SINUSITIS
Interventions: Cyclamen Europaeum; Drug
Lead sponsor: Dey; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Birmingham, Alabama • Oxford, Alabama • Jonesboro, Arkansas + 19 more

Search by objective public record fields.

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Parents Workgroup About Emotion Regulation

Social Ecology and the Prevention of Suicide and Aggression in African American Youth

Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Collection of Gastrointestinal Malignant and Non-malignant Human Samples

Music vs. No Music During Cesarean Delivery on Patient Satisfaction

Ventricular Arrhythmia Ablation With the Use of Non-Invasive ECG Imaging Technology

Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder

SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke

Imitation-based Dog Assisted Intervention, for Children With Developmental Disabilities.

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Families

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

Oxybutynin and Omega-3 for OAB (Overactive Bladder)

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Pain Relief Satisfaction With New Educational Materials

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Effects of Botox in Obstructed Defecation Syndrome

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis